NCT06700889

Brief Summary

The goal of this at-home, remote study is to understand the relationship between blood sugars and sleep in adults living with Cystic Fibrosis Related Diabetes (CFRD).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

November 18, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 22, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 8, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 8, 2026

Completed
Last Updated

January 9, 2026

Status Verified

January 1, 2026

Enrollment Period

1.1 years

First QC Date

November 18, 2024

Last Update Submit

January 8, 2026

Conditions

Keywords

Cystic Fibrosis Related DiabetesTube FeedsCircadian RhythmDiabetesHome Enteral NutritionCircadian misalignmentNutrition

Outcome Measures

Primary Outcomes (1)

  • Completion Rate

    Primary feasibility measure, defined by the completion of all study procedures and the return of study devices after the 10-day study period.

    10 days

Secondary Outcomes (18)

  • Enrollment Rate

    Through study completion, an average of 1 year

  • Percentage of time glucose levels

    10 days

  • Number of CGM Days

    10 days

  • Number of Actigraphy Days

    10 days

  • Number of Completed At-Home Kits (HbA1c)

    10 days

  • +13 more secondary outcomes

Study Arms (2)

HEN group

This group will include participants who habitually use home enteral nutrition (HEN).

No HEN Group

This group will include participants who do not use home enteral nutrition (HEN).

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Cystic fibrosis-related diabetes patients living in the US and identified from various sources: Rally website, the MGH Adult CF Program, the CF Foundation EnVision program, and the Oley Foundation.

You may qualify if:

  • Adult men or non-pregnant women volunteers (age 18-79) Able and willing to give consent and comply with procedures Known diagnosis of CF Related Diabetes (CFRD) and clinically stable with no significant changes in therapies within the prior 3 months
  • Concomitant Medications:
  • A. No initiation of an investigational drug within prior 28 days B. No initiation of new chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, Cayston®) within prior 28 days C. No acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids for respiratory tract symptoms within prior 14 days D. No starting/stopping modulator therapy in the prior 3 months

You may not qualify if:

  • Blind, deaf, or unable to speak English Pregnant, nursing, or plan on pregnancy Current use of melatonin and unwilling to stop during the study With skin condition that precludes wearing sensors Within the last 4 weeks, acute CF exacerbation requiring IV antibiotics or hospitalization Major changes in diet or physical activity level in the last 4 weeks Untreated sleep and circadian disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Related Links

MeSH Terms

Conditions

HyperglycemiaSleep Initiation and Maintenance DisordersChronobiology DisordersDiabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental DisordersEndocrine System Diseases

Study Officials

  • Hassan S Dashti, Ph.D., R.D.

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 18, 2024

First Posted

November 22, 2024

Study Start

November 18, 2024

Primary Completion

January 8, 2026

Study Completion

January 8, 2026

Last Updated

January 9, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

We do not plan to share Individual Participant Data (IPD) with other researchers as the information collected, which includes detailed glucose profiles, sleep patterns, and circadian rhythm data from individuals with CFRD, is classified as protected health information.

Locations